Amphastar Pharmaceuticals: Analyzing Bull Put Options Strategy for 2026

Amphastar Pharmaceuticals, Inc. is attracting attention as analysts rate the company a Buy, with an estimated upside of approximately 81% to a fair value of $33. This optimism persists despite anticipated margin pressures for the year 2026. The company is experiencing a decline in sales from its legacy products but is expected to achieve mid- to high-single-digit revenue growth, primarily driven by its product Baqsimi and upcoming launches.

The pharmaceutical landscape is challenging for Amphastar. While the company faces declining sales in established drugs, it is banking on new product introductions to maintain momentum. Analysts project that operating margins may dip to 22% in 2026 as expenses rise. However, a recovery to 26% is anticipated by 2030 as the company begins to see the benefits of its higher-margin pipeline products.

To navigate these challenges, a bull put options strategy is suggested. This approach may provide a more favorable risk-reward profile compared to direct equity investment, particularly given Amphastar’s current market position, characterized by a lack of a strong competitive moat and limited high-growth prospects.

In July of last year, I last discussed Amphastar Pharmaceuticals. The company, which combines both generic and proprietary drugs in its portfolio, was identified as undervalued at that time. This perspective remains relevant as investors evaluate the potential of its pipeline and market strategy.

It is important to note that I have a beneficial long position in AMPH shares, which I hold through stock ownership, options, or other derivatives. My analysis is independent, and I am not receiving compensation for this article other than from Seeking Alpha. Furthermore, I have no business relationship with any company mentioned in this discussion.

Investors should proceed with caution, as past performance does not guarantee future results. This article does not serve as a recommendation for any investment strategy and reflects my personal opinions. Seeking Alpha operates as a platform for various authors, including both professional and individual investors, and does not act as a licensed securities dealer or investment adviser.

As Amphastar Pharmaceuticals continues to navigate its market challenges, the focus will be on how effectively it can leverage new product launches to offset declines in legacy product sales. The bull put options strategy offers a tactical approach for investors looking to engage with this evolving company while considering the inherent risks involved.